



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : A61K 37/36	A1	(11) International Publication Number: WO 93/12811 (43) International Publication Date: 8 July 1993 (08.07.93)
(21) International Application Number: PCT/DK92/00379 (22) International Filing Date: 16 December 1992 (16.12.92) (30) Priority data: 2046/91 20 December 1991 (20.12.91) DK 1364/92 10 November 1992 (10.11.92) DK (71) Applicant: NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsvaerd (DK). (72) Inventors: SØRENSEN, Hans, Holmegaard ; Joachim Rønnowsvej 21, DK-2830 Virum (DK). SKRIVER, Lars ; Ellesøpark 24, DK-2930 Vedbæk (DK). HOELGAARD, Annie, Rassing ; Kastanievej 35, DK-2840 Holte (DK). (74) Agent: NOVO NORDISK A/S; Patent Department, KNil, Novo Allé, DK-2880 Bagsvaerd (DK).		(81) Designated States: AU, BG, BR, CA, CS, FI, HU, JP, KP, KR, NO, NZ, PL, RO, RU, UA, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: A STABILIZED PHARMACEUTICAL FORMULATION COMPRISING GROWTH HORMONE AND HISTIDINE (57) Abstract A pharmaceutical preparation comprising a growth hormone and histidine or a derivative of histidine as additive or buffering substance shows a very high stability against deamidation, oxidation and cleavage of peptide bonds. The stability of the product allows for the storing and shipment thereof in a lyophilized state or in the form of a dissolved or re-dissolved preparation at ambient temperature. Crystallization of growth hormone in the presence of histidine or a derivative thereof gives rise to a higher yield of crystals having a higher purity than known methods.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LJ	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

TITLE

A stabilized pharmaceutical formulation comprising growth hormone and histidine.

FIELD OF THE INVENTION

The present invention relates to a stabilized pharmaceutical formulation comprising growth hormone, to a method of making such formulation, crystals of growth hormone comprising histidine or a derivative thereof, a method of preparing such crystals and the use of histidine or derivatives of histidine for stabilizing a formulation of growth hormone.

10 BACKGROUND OF THE INVENTION

The growth hormones (GH) from man and from the common domestic animals are proteins of approximately 191 amino acids, synthesized and secreted from the anterior lobe of the pituitary gland. Human growth hormone consists of 191 amino acids.

15 Growth hormone is a key hormone involved in the regulation of not only somatic growth, but also in the regulation of metabolism of proteins, carbohydrates and lipids. The major effect of growth hormone is to promote growth.

The organ systems affected by growth hormone include the skeleton, connective tissue, muscles, and viscera such as liver, intestine, and kidneys.

Until the development of the recombinant technology and the cloning of the growth hormone gene now giving rise to production of e.g. human growth hormone (hGH) and Met-hGH in industrial scale, human growth hormone could only be obtained by
25 ~~extraction from the pituitary glands of human cadavers.~~ The very limited supplies of growth hormone restricted the use thereof to longitudinal growth promotion in childhood and puberty for treatment of dwarfism, even though it has been

proposed for inter alia treatment of short stature (due to growth hormone deficiency, normal short stature and Turner syndrom), growth hormone deficiency in adults, infertility, treatment of burns, wound healing, dystrophy, bone knitting, 5 osteoporosis, diffuse gastric bleeding, and pseudoarthrosis.

Furthermore, growth hormone has been proposed for increasing the rate of growth of domestic animals or for decreasing the proportion of fat in animals to be slaughtered for human consumption.

10 Pharmaceutical preparations of growth hormone tend to be unstable. Degradation products such as deamidated or sulfoxylated products and dimer or polymer forms are generated - especially in solutions of growth hormone.

The predominant degradation reactions of hGH are 1) deamida-
15 tion by direct hydrolysis or via a cyclic succinimide intermediate to form various amounts of L-asp-hGH, L-iso-asp-hGH, D-asp-hGH, and D-iso-asp-hGH (ref 1), 2) oxidation of the methionine residues in positions 14 and 125 (ref 4-9), and 3) cleavage of peptide bonds.

20 Deamidation especially takes place at the Asn in position 149.

hGH is rather easily oxidized in positions 14 and 125, especially in solution (4-8).

The oxidation of hGH in solution forming sulfoxides is normally due to the oxygen dissolved in the preparation. The
25 solubility of oxygen in distilled water is about 200 μM (9). As the concentration of hGH in a preparation comprising 4 IU/ml is 1.3 mg/ml corresponding to 60 nM hGH, oxygen will, at normal storing conditions, be present in an excess of
30 about 3000 times the stoichiometric amount for oxidation of

hGH. It is not feasible to try to solve the problem by degassing of buffers before tapping and packing the preparations.

At present, it is not believed that these degradation products should have toxic or altered biological activity or receptor binding properties, but there is indication to the effect that the conformation stability of the sulfoxides is reduced as compared to native hGH.

For the development of a stable, dissolved preparation comprising hGH it is of importance to know the rate of formation of sulfoxides as well as means to control the oxidation.

The kinetics of degradation depend on temperature, pH and various additives or adjuvants in the hGH formulation.

Due to the instability, growth hormone is, at present, lyophilized and stored in the lyophilized form at 4°C until it is reconstituted for use in order to minimize the degradation.

The lyophilized pharmaceutical preparations comprising hGH are, at present, reconstituted by the patient and then stored at a low temperature, often at about 4°C in the refrigerator as a solution during the period of use of up to 14 days, during which some degradation will take place.

Furthermore, the process of reconstitution of the lyophilized growth hormone tends to provide difficulties for the patient.

Thus, it is at present preferred to reconstitute the growth hormone as late as possible before use and to store and ship the preparation in a lyophilized state. The chain from the manufacturer to the pharmacy is apt for handling the prepara-

4.

tions at a controlled low temperature of e.g. 4°C which allows for a long shelf life of up to two years.

However, the extended use of pen systems for self-medication and the expanded field of use calls for a preparation which
5 is stable for a sufficient long time with the end user under conditions where "sufficient" cooling is not always available.

Preferably, a preparation should be stable with the end user in a lyophilized state for about one month and additionally
10 for one month in a reconstituted state in a pen device for the intended period of use of a cartridge.

Thus, there is a need for more stable preparations of growth hormone being stable in a lyophilized state at a relative high temperature for a period and additionally for a period
15 of use at a relatively high temperature in solution. Such stabilization is of very great importance when moving the administration of the growth hormone from clinics to the homes of the individuals to be treated where optimal storage may not be available as indicated above.

20 Furthermore, the shift in pattern of administration of growth hormone to the use of pen devices calls for a stable dissolved preparation comprising growth hormone in order to facilitate the handling to be performed by the patient. A stable dissolved preparation comprising growth hormone may be pro-
25 duced ready to use in the form of cartridges fitting into the pen device used by the patient who may then avoid the reconstitution of the preparation and, hence, will not have to be in the possession of a lyophilized preparation, a suitable vehicle for reconstitution as well as the necessary skill and
30 sterile equipment for sterile reconstitution of the preparation.

For safety reasons it will also be desirable to avoid the reconstitution of a lyophilized preparation just before the use of the preparation.

Furthermore, it would also be an advantage to avoid the lyophilization step in the production of growth hormone preparations. Lyophilization is a time consuming and costly process and is also often a "bottleneck" in the production due to the limited capacity of the freeze drier.

Thus, there is a need to reduce the rate of the degradation processes in order to allow for dissolved hGH preparations being stable during shelf life and during the period of use of up to one month.

Prior attempts to stabilize hGH has not fully succeeded in preventing the formation of dimer. The problems associated with dimer formation is e.g noted in Becker, G.W., Biotechnology and Applied Biochemistry 9, 478 (1987).

International Patent Publication No. WO 89/09614 and Australian patent application No. 30771/89 disclose a stable pharmaceutical formulation containing human growth hormone, glycine, and mannitol. Such a preparation shows improved stability during normal processing and storage in a lyophilized state as well as in the period of use after the reconstitution.

Published European patent application No. 303 746 discloses that animal growth hormone may be stabilized with various stabilizers to give decreased formation of insolubles and preservation of the soluble activity in aqueous environments, such stabilizers including certain polyols, amino acids, polymers of amino acids having a charged side group at physiological pH, and choline salts. Polyols are selected from the group consisting of non-reducing sugars, sugar alcohols, sugar acids, pentaerythritol, lactose, water-soluble dextrans and Fi-

coll; amino acids are selected from the group consisting of glycine, sarcosine, lysine or salts thereof, serine, arginine or salts thereof, betaine, N,N,-dimethyl-glycine, aspartic acid or salts thereof, glutamic acid or salts thereof; a polymer of an amino acid having a charged side group at physiological pH may be selected from polylysine, polyaspartic acid, polyglutamic acid, polyarginine, polyhistidine, polyornithine and salts thereof; and choline derivatives are selected from the group consisting of choline chloride, choline dihydrogen citrate, choline bitartrate, choline bicarbonate, tricholine citrate, choline ascorbate, choline borate, choline gluconate, choline phosphate, di(choline)sulphate and dicholine mucate.

EP 374120 discloses a stabilized preparation of growth hormone comprising a buffered polyol excipient comprising a polyol having three hydroxy groups and a buffer to achieve a pH in a range in which the growth hormone retains its bioactivity for a sufficient period of time. Histidine is mentioned as a buffer for a polyol having three hydroxy groups.

20 BRIEF DESCRIPTION OF THE INVENTION

It has now surprisingly been found that a preparation of human growth hormone comprising only histidin or a derivative thereof as additive or buffering substance in an amount of from 0.1 to 12 mg histidine or derivative thereof per mg of growth hormone shows a very high stability against deamidation, oxidation and cleavage of peptide bonds. The stability of the product allows for the storing and shipment thereof in a lyophilized state or in the form of a dissolved or re-dissolved preparation.

EP 303746 mentions polyhistidine as a potential stabilizer for animal growth hormone but there is no indication whether it stabilizes an animal growth hormone or human growth hormone.

EP 374120 teaches that histidine hydrochloride may be used as a buffer for buffering a polyol having three hydroxy groups for improving the stability of a growth hormone preparation in the form of a solution comprising a high concentration of 5 growth hormone and a polyol as stabilizer. Histidine hydrochloride must be added in an amount of about 3% by weight of the solution corresponding to a concentration of ~0.15 M solution of histidine hydrochloride. EP 374120 also teaches that histidine alone does not impart chemical and physical 10 stability to a growth hormone preparation.

The preparation of the invention may be in the form of a lyophilized powder to be reconstituted later using conventional vehicles such as distilled water or water for injection or in the form of a solution or a suspension of crystals comprising 15 growth hormone. Such vehicles may comprise conventional preservatives such as m-cresol and benzyl alcohol.

A preferred embodiment of the invention is in the form of a pharmaceutical preparation of human growth hormone comprising histidin or a derivative thereof in the form of a buffered 20 aqueous solution of growth hormone buffered with histidine buffer. Such preparation is in a ready-to-use form and may be stored and shipped as an aqueous solution without any considerable degradation. L-histidine has a pKA of 6.0 and is, accordingly suitable as a buffer itself at pH 6.5.

25 The formulation of histidine at pH 6.5 is considered stable at 25°C for almost 50 days.

A further, preferred embodiment of the invention is in the form of a pharmaceutical preparation of human growth hormone comprising histidin or a derivative thereof in the form of a 30 ~~buffered aqueous suspension of crystals of growth hormone~~ buffered with histidine buffer. Such a preparation is very stable and keeps the growth hormone in a crystalline phase during the storing and shipment in a ready-to-use form giving

an even lower tendency to degrade. Such preparation acts like a dissolved preparation when injected, i.e. there is no sustained release of the human growth hormone.

For stability reasons the pH of a solution or suspension preparation is preferably adjusted to a value in the interval from 2-9. Preparations having a pH from 5 to 8 and especially a pH from 6 to 7.5 are more preferred.

In order to obtain the stabilizing effect, the concentration of histidin is preferably from 1 mM to 100 mM. More preferred, the concentration of histidin added is in an amount from 2 to 20 mM, most preferred from 5 to 15 mM.

Addition of 10% ethanol or 5% methanol resulted in more than 20% reduction in the deamidation.

The preparations of the invention may also be in the form of a lyophilized powder or "cake" comprising growth hormone or a growth hormone derivative, and histidin or a derivative thereof in an amount from 0.1 to 12 mg histidine or derivative thereof per mg growth hormone or growth hormone derivative and a bulking agent for lyophilization selected from the group consisting of sugar alcohols and disaccharides and mixtures thereof. A sugar alcohol is preferably mannitol.

Lyophilized preparations according to the invention comprising sucrose are preferred due to a very high stability and preparations comprising sucrose and mannitol are especially preferred combining very high stability with a very good processability giving firm lyophilized products being readily dissolvable and very stable in solution for an extended period of time after dissolution. Further preferred preparations according to the invention are preparations comprising mannitol and trehalose as bulking agent for the lyophilization. Preparations according to the invention comprising man-

nitrol and a disaccharide normally comprises about equal amount of the two constituents on a weight basis.

The amount sucrose present in the preparations of the invention may vary within wide limits. The ratio of growth hormone 5 to sucrose may vary from 0.005 to 1.5 on a weight basis. Thus, the amount of sucrose may be from 0.67 to 200 mg per mg of growth hormone, an amount of from 1.1 to 50 mg per mg of growth hormone being preferred.

10 Lyophilization of hGH in histidine buffer does not give rise to any problems. The rate of deamidation is reduced by 20% on standing after redissolving as compared to phosphate buffer.

The pharmaceutical preparation of the invention may furthermore comprise salts conventionally used in order to facilitate the processing thereof, e.g. the lyophilization or reconstititution. 15

Another way of stabilizing growth hormone according to the invention is to form crystals of growth hormone giving a good protection against degradation. It has surprisingly been found that preparations of growth hormone in the form of crystals 20 comprising histidine fulfil the above-mentioned needs. The crystals in dried form may be used directly as a GH preparation to be reconstituted before use in the conventional manner.

Thus, the present invention also relates to crystals of 25 growth hormone or a growth hormone derivative comprising histidine or a derivative thereof and an organic or inorganic cation. It has been shown that the quality of such crystals is better than the quality obtained using previous formulations.

Although readily available in quantities sufficient for crystallization, no successful crystallization of GH has been reported so far. Micro crystals, or amorphous material have been reported from a variety of sources: (Jones et al., Bio-
5 Technology (1987) 5, 499 - 500; Wilhelmi et al., J.Biol.Chem. (1984) 176, 735 - 745; Clarkson et al., J.Mol.Biol. (1989) 208, 719 - 721; and Bell et al., J.Biol.Chem. (1985) 260, 8520 - 8525.

The hanging drop method is the most common method used in
10 attempts for crystallizing GH. Apparently due to heterogeneity growth hormone preparations the size and the shape of the crystals reported vary significantly. The largest crystals have been reported by Jones et al. (1987). For their successful experiments they used a mixture of polyethylene
15 glycol 3500 and beta octyl glucoside at neutral pH. Clarkson et al. (1989) reported that the use of lower alcohols and acetone permitted the generation of crystals of 0.001 to 0.005 cubic mm with varying shapes. None of the known methods are however suitable for commercial production of GH crystals
20 a.o. due to the fact that periods of growth of from several weeks up to one year are needed.

Bovine growth hormone has been formulated for veterinarian use in a mixture of divalent ions and an oil (EP 343 696). By addition of $ZnCl_2$ to either bovine or porcine growth hormone
25 in the presence of lipids undefined particles were produced to form a prolonged release formulation. The growth hormone was dispersed in the carrier in such a way as to trap 1 to 4 Zn molecules per growth hormone molecule. The solutions were prepared in the presence of varying concentrations of dena-
30 turing solutes (1 to 4 M of urea) at high pH (9.5). A reproduction of this process with hGH has shown that it is not possible to produce crystals in this way.

From the literature it is well known that the presence of divalent cations during the process of crystallization of

insulin permits not only excellent orientation during analysis, but also improved physical conditions for the crystallization (see e.g. US pat. no. 2174862). Growth hormone is, however, more than three times larger than insulin and has a totally different conformation. Surprisingly it has now been shown that the addition of cations to solutions containing hGH and histidine or a derivative of histidine renders possible the generation of stable, uniform crystals of the growth hormone in high yields. Furthermore, the period of time necessary for the formation of high quality crystals of hGH is relatively short.

A further aspect of the invention is a method for preparing crystals of growth hormone and histidine or a derivative of histidine comprising the steps of:

- 15 a) forming a solution of growth hormone or growth hormone derivative in a solvent and adding histidine or a derivative of histidine and optionally adjusting the pH to a value from 5 to 8 using hydrochloric acid
- b) adding organic or inorganic cations
- 20 c) crystallizing the solution at a temperature from about 0°C to about 30°C, and
- d) isolating the crystals formed by a manner known per se.

It has been found that crystallizing hGH in the presence of histidine or a derivative thereof gives a higher yield of crystalline hGH in the form of bigger and more pure and uniform crystals than crystallization in the presence of phosphate buffer normally used for formulation of preparations of hGH. Thus, the isolation and purification of the crystals is facilitated.

The yield of crystals has been increased by ~ 20% when carrying out the crystallisation in the presence of histidine as compared with crystallizing from previous formulations.

The starting material, the growth hormone, may be a concentrate obtained directly from the fermentation broth or a conventional lyophilized preparation which is dissolved in the solvent and adjusted to a concentration of preferably more than 0.1 mg/ml, preferably a concentration from 4 to 7 mg/ml and most preferred a concentration of 6 mg/ml. The solvent used in step a) is suitably an aqueous buffer such as phosphate buffer or histidine buffer.

The crystallization is allowed to proceed for a period from 1 to 120 hours, preferably from 5 to 72 hours and most preferred from 20 to 48 hours at a temperature. The temperature is preferably from 4 to 25°C.

The pH in step a) is normally from 5.0 to 7.5, preferably from 5.0 to 6.8, more preferred from 5.8 to 6.5, and most preferred from 6.0 to 6.3.

The concentration of histidine or histidine derivative in step a) may vary from 5-25 mM, 5-15 mM being preferred, in order to have crystals of appropriate size and quality as stated above.

Divalent cations are preferred and inorganic cations such as Zn^{++} has been found to be well suited for the fast formation of stable GH crystals. Also mixtures of cations can be used.

The cation should be added in an amount providing fast and efficient formation of well defined crystals. The upper limit for the amount of added cation is the amount which would cause unspecific precipitation of substantial amounts of amorphous material.

When using Zn^{++} , suitable concentrations will typically be from about 0.2 to 10 mol Zn^{++} /mol GH. However, if the crystallization reaction mixture contains a buffer or other compound which is capable of binding the cation, e.g. in a complexed form, a higher added concentration of the cation will be needed for the crystallization process in order to compensate for this binding.

Zn^{++} will preferably be used in an amount which will cause formation of GH crystals having a molar ratio between Zn^{++} and GH from about 0.2 to about 10, more preferred from about 0.5 to about 5 and preferably from about 0.5 to about 2.

When using other inorganic cations, the concentration may be varied between 0.5 and 10 mol cation/mol GH.

In a preferred embodiment of the invention an organic solvent or a mixture of organic solvents is added in step a).

Suitable organic solvents to be added for the crystallization may be chosen from short chained aliphatic, alicyclic or aromatic alcohols and ketones such as methanol, ethanol, 1- and 2- propanol, cyclohexanol, acetone, and phenol or m-cresol. Preferred organic solvents are ethanol and acetone, ethanol being most preferred.

The solution may be seeded by adding small and well defined crystals of hGH of hexagonal or needle shape, but preferably no seeding is carried out.

The concentration of the organic solvent may be from 0.1 to 50% v/v, preferably from 0.1 to 30%, more preferably from 0.1 to 20%, even more preferably from 5 to 15% and most preferred from 6 to 12% v/v.

The present process may be used as a fast and efficient downstream processing of the growth hormone in question, due to the formation of crystals in large volumes of solutions.

When using ethanol as the organic solvent, the concentration is suitably between 0.1 and 20%, more preferably between 5 and 15% and preferably from 6 to 12% (v/v).

The crystals formed may be isolated by conventional methods such as centrifugation or filtration, washing and optionally lyophilization to remove traces of organic solvents.

10 The size of the crystals will be dependent on the Zn^{++} to GH ratio and the choice and content of solvent used in the process.

hGH crystals according to the present invention have been shown to have a biological potency similar to that of a solubilized hGH standard in in vitro tests. The novel GH crystals can thus be used for the same indications as the commercially available hGH preparation.

Still another aspect of the invention relates to the use of histidine or a derivative thereof for the preparation of a
20 stabilized preparation of growth hormone.

The pharmaceutical preparations of the invention are preferably presented in a unit dose form comprising from 4 IU to 100 IU growth hormone per dose.

In the present context "growth hormone" may be growth hormone
25 from any origin such as avian, bovine, equine, human, ovine, porcine, salmon, trout or tuna growth hormone, preferably bovine, human or porcine growth hormone, human growth hormone being most preferred. The growth hormone used in accordance with the invention may be native growth hormone isolated from

a. natural source, e.g. by extracting pituitary glands in a conventional manner, or a growth hormone produced by recombinant techniques, e.g. as described in E.B. Jensen and S. Carlsen in Biotech and Bioeng. 36, 1-11 (1990). The "growth hormone derivative" may be a truncated form of growth hormone wherein one or more amino acid residues has (have) been deleted; an analogue thereof wherein one or more amino acid residues in the native molecule has (have) been substituted by another amino acid residue, preferably the residue of a naturally occurring amino acid, as long as the substitution does not have any adverse effect such as antigenicity or reduced action; or a derivative thereof, e.g. deamidated or sulfoxidated forms of the growth hormone or forms having an N- or C-terminal extension such as Met-hGH, Met-Glu-Ala-Glu-hGH or Ala-Glu-hGH. The preferred growth hormone is hGH.

The term "derivatives of histidin" is used, for the present purpose, to designate amides and esters of histidine such as the methyl or ethyl ester, dipeptides such as His-Gly, His-Ala, His-Leu, His-Lys, His-Ser, and His-Phe, and analogues or derivatives of His such as imidazol, des-amino-His or poly-His. For the sake of simplicity, the contents of histidine or a derivative thereof in the preparations of the invention is calculated and using the molar weight of histidine itself.

The term "salts" used to designate additional agents for facilitating the processing or reconstitution of pharmaceutical preparations comprises conventional additives such as alkaline metal, alkaline earth metal or ammonium salts of organic acids such as citric acid, tartaric acid or acetic acid, e.g. sodium citrate, sodium tartrate or sodium acetate, or of mineral acids such as hydrochloric acid, e.g. sodium chloride.

In the present context "high stability" is obtained when the preparation is more stable than the conventional formulations comprising phosphate buffer.

A "sugar alcohol" may e.a. be mannitol, xylitol, erythritol, threitol, sorbitol or glycerol.

In the present context "disaccharide" is used to designate naturally occurring disaccharides such as sucrose, trehalose, 5 maltose, lactose, sepharose, turanose, laminaribiose, isomaltose, gentiobiose or melibiose.

The solvent used in the preparations of the invention may be water, alcohols such as ethyl, n-propyl or isopropyl, butyl alcohol or a mixture thereof. The solvent may comprise a pre-
10 servative such as m-cresol or benzyl alcohol.

BRIEF DESCRIPTION OF THE DRAWINGS

The invention is described more in detail with reference to the drawings in which

Fig. 1 shows a photo of crystals of hGH prepared in the pre-
15 sence of phosphate buffer (without addition of histidine) (Magnification 400X), and

Fig 2 shows a photo of crystals of hGH according to the invention formed in the presence of histidine buffer. (Magnification 400X).

20 DETAILED DESCRIPTION OF THE INVENTION

The invention is explained more in detail in the below Examples which illustrate the invention. They are not to be considered as limiting the scope of the invention being defined by the appended claims.

EXPERIMENTAL PART**EXAMPLE 1.**Reduction of the deamidation.

The rate of deamidation was examined at 37°C for hGH preparations comprising 4IU and 12IU at pH 6.5 in His buffer as compared to phosphate buffer at the same pH.

The hGH preparation comprising 4 IU having the composition A was prepared by dissolving 13.3 mg hGH in 10 ml 10 mM histidine buffer prepared by dissolving 15.5 mg histidine in 100 ml deionized water containing 0.9% benzyl alcohol and adding 0.1 N hydrochloric acid to pH 6.5. The preparation comprising 12 IU was prepared by dissolving 40 mg hGH in the same constituents as stated above.

The hGH preparation comprising 4IU having the composition B was prepared by dissolving 13.3 mg hGH in 10 ml 10 mM disodium phosphate prepared by dissolving 17.8 mg disodium-hydrogen-phosphate in 100 ml deionized water, containing 0.9% (v/v) of benzyl alcohol and adding 0.1 N phosphoric acid to pH 6.5. The preparation comprising 12 IU was prepared by dissolving 40 mg hGH in the same constituents as stated above.

Composition A:

10 mM His
0.9% benzyl alcohol
25 HCl ad pH 6.5

Composition B:

10 mM disodium phosphate
0.9% benzyl alcohol
phosphoric acid ad pH 6.5

The preparations were examined by IE-HPLC for the contents of desamido-hGH immediately after the reconstitution and after 7 days at 37°C. The results appear from the below Table 1.

TABLE 1.
5 Deamidation.

	Preparation	Desamido %
<hr/>		
10	Buffer A 4IU/ml	1.7
	Start 12 IU/ml	2.1
	Buffer A 4IU/ml	10.1
	7 days at 37°C 12IU/ml	10.4
	Buffer B 4 UI/ml	1.8
	Start 12 IU/ml	2.3
15	Buffer B 4 UI/ml	16.9
	7 days at 37°C 12 IU/ml	14.9

From the above figures it appears that the deamidation of hGH is significantly reduced at 37°C in histidine buffer as compared with phosphate buffer.

EXAMPLE 2:

Reduction of the deamidation in the presence of histidine or histidine derivatives.

*His
deriv's tested* { The rate of deamidation was examined at 25°C for hGH preparations comprising 6 IU hGH at pH 6.5 and at pH 7.3 in 5 mM, 10 mM and 100mM His buffer as compared to 8 mM phosphate buffer at the same pH. Furthermore, the histidine derivatives His-Gly, His-Ala, His-Leu, His-Lys, His-Phe, His-Ser, Histidine methyl ester, histidinol, imidazol, imidazol-4-acetic acid, and histamine were tested.

The hGH preparations were prepared by dissolving 20 mg hGH in 10 ml of histidine buffer of the desired strength prepared by dissolving 7.8 mg, 15.5 mg, and 155.2 mg, respectively, of histidine in 10 ml deionized water containing 0.9% (v/v) of benzyl alcohol and adding 0.1 N hydrochloric acid to the stated pH.

The hGH formulations stated in the below Table 2 were stored at 25°C and analyzed for the desamido contents after 14 and 30 days by IE-HPLC. The results appear from the below Table 2.

Table 2.

Contents of desamido hGH as determined by IE-HPLC as a function of the formulation and the time in solution at 25°C:

20

	Formulation (*)	Formation of desamido compound at 25°C	
		14 days (')	30 days
5	5 mM His pH 6.5	6.5	9.1
	5 mM His pH 7.3	11.0	17.4
	10 mM His pH 6.5	6.8	9.7
	10 mM His pH 7.3	11.3	16.6
	100 mM His pH 6.5	9.8	15.2
10	100 mM His pH 7.3	19.3	28.8
	8 mM di-Na-Phosfat pH 6.5	7.8	10.8
	8 mM di-Na-Phosfat pH 7.3	15.2	20.3
15	8 mM di-Na-phosfat pH 6.5, 0.3% m-cresol	9.4	13.2
	10 mM Asp, pH 6.5	21.7	nd
	10 mM Glu, pH 6.5	14.8	nd
20	10 mM His-Gly,	5.6	8.1

21

	pH 6.2		
	10 mM His-Ala	6.2	8.5
	pH 6.5		
	10 mM His-Leu	8.8	12.3
5	pH 6.5		
	10 mM His-Lys	8.6	12.0
	pH 6.5		
	10 mM His-Phe	7.5	11.3
	pH 6.5		
10	10 mM His-Ser	22.0	nd
	pH 6.3		
	10 mM His-methyl- ester, pH 6.5	4.6	5.2
15	10 mM histidinol	27.4	nd
	pH 6.5		
	10 mM imidazol	9.2	12.2
	pH 6.5		
	10 mM imidazol- 4-acetic acid	10.3	14.2
20	pH 6.5		
	10 mM Histamine	9.8	12.2
	pH 6.5		

*: Comprises 0.9% benzyl alcohol, except formulation No.9
The contents of desamido-hGH in starting material was: 2.1 %

From the above Table 2 it appears that the de-amidation of hGH is reduced by approximately 20% by the addition of histidine as compared with phosphate buffer at pH 6.5 and 7.3. Furthermore, a reduction of the pH from 7.3 being the conventional pH of commercial hGH preparations to 6.5 in itself gives rise to a reduction of the rate of de-amidation by 50%.

Histidinol does not seem to stabilize the preparations under the test conditions, and addition of histidine in larger amounts does not add but rather detract from the desired effect.

Comparable results are seen to be obtained using histidine analogues such as imidazol, histamine, and imidazol-4-acetic acid as well as the histidine methyl ester giving rise to the formation of only 3.1% desamido-hGH after 30 days at 25°C, allowing for a life-time of the preparation of 3-4 months.

Addition of Asp or Glu increases the rate of deamidation as compare to phosphate at pH 6.5.

Addition of dipeptides of the type His-X shows positive effect for His-Gly and His-Ala, whereas His-Ser reduces the stability to de-amidation.

The above results show that the rate of de-amidation is reduced by lowering the pH and by adding histidine in a low concentration, preferably about 5mM-10mM. The rate of de-amidation may be reduced by more than 50% by lowering the pH and substituting the phosphate buffer with histidine.

The use of m-cresol or benzyl alcohol as preservative seems to have no influence on the rate of de-amidation.

Split-formation (hydrolysis of peptide bonds) is reduced by histidine at pH 6.5 in comparison with phosphate.

5 EXAMPLE 3.

Reduction of the formation of sulfoxide.

The dependency of the pH and the type of buffer was examined.

Dependency of pH:

Formulation:

- 10 A commercial hGH preparation (Norditropin®, 12 IU/ml) comprising bicarbonate, glycine and mannitol + 0.9% benzyl alcohol was adjusted to pH 8.3, 8.0, 7.5, 7.0, 6.5 and 6.0 using 0.1 N hydrochloric acid, and the samples were left at 37°C. Analysis was carried out by RP-HPLC after 0, 7 and 14 days.
- 15 The results appear from the below Table 3.

Table 3.

Formation of Sulfoxide

	Sample	Temp °C	Days	Sulfoxide %
5	pH 8.37	-	0	1.0
	pH 8.37	37	7	9.0
	pH 8.04	37	7	8.7
	pH 7.52	37	7	8.3
	pH 7.01	37	7	7.7
10	pH 6.52	37	7	6.5
	pH 6.02	37	7	4.8
	pH 8.37	37	14	14.9
	pH 8.04	37	14	14.5
	pH 7.52	37	14	14.0
15	pH 7.01	37	14	12.9
	pH 6.52	37	14	11.1
	pH 6.02	37	14	7.7

As will be appreciated, the formation of sulfoxide of hGH is reduced when lowering the pH from 8.4 to 6.0.

Type of Buffer, pH:

A B-hGH preparation comprising 12 mg/ml distilled water was diluted in the proportion 1+10 with various buffers in a concentration of 15 mM and optional added further additive(s). The samples were left at 25°C, and analysis by RP-HPLC was carried out after 10 and 34 days. The results of the RP-HPLC and optional additives appear from the below Table 4.

EXAMPLE 4Crystallization of hGH in the presence of phosphate or histidine buffer

Aliquots of a hGH solution prepared according to Dalboe et al Biotechnology (1987), 5, 161-164, in concentrations of 6 mg/ml were incubated in 10 mM phosphate or 10 mM histidin buffer at pH 6.2. To each of the samples was added ethanol to a final concentration of 7.5% (v/v) followed by addition of zinc acetate solution to a final zinc concentration of 1.34 mol Zn/mol hGH in the case of phosphate buffer and 5.5 mol Zn/mol hGH in the case of histidin buffer.

The crystals were grown in suspension for 16 hrs and the crystallization was monitored by phase contrast microscopy. The crystals formed in histidine buffer have a well defined uni-sized hexagonal appearance comprising little or no amorphous contaminants (Fig. 1). On the contrary, hGH crystals formed in phosphate buffer under the exact identical conditions show a much more pronounced heterogenous appearance comprising a considerable amount of amorphous material (Fig. 2).

The crystals were allowed to grow for a further 5 days. Crystals formed in both histidine and phosphate buffer were collected by centrifugation and the crystals were dissolved in 7 M urea followed by hGH analysis.

<u>Buffer</u>	<u>% crystals</u>	<u>% free hGH</u>
25 Histidine	65	35
Phosphate	55	45

Thus histidine buffer provides better conditions for hGH crystallization with respect to both yield of crystals and quality.

EXAMPLE 5

5 The stability of lyophilized hGH preparations comprising histidin and succrose or mannitol compared to a conventional hGH preparation containing phosphate, glycine and mannitol.

The following preparations 1-8 were made by desalting a hGH solution into the stated histidin buffers. After adjusting
10 the hGH concentration to 6 IU/ml with the various histidin buffers, the stated amounts of mannitol and sucrose were dissolved.

Preparations 9 corresponds to a conventional hGH preparation and is used as reference.

15 All hGH solutions 1-9 were filled into vials a 1 ml and lyophilized.

Analyses of hGH were performed after reconstitution with a 0.9% solution of benzyl alcohol.

1. hGH 6 IU/ml
20 Adjusted to pH 6.5 using HCl
Mannitol 33 mg/ml

2. hGH 6 IU/ml
Adjusted to pH 6.5 using HCl
Sucrose 62 mg/ml

28

3. hGH 6 IU/ml
Adjusted to pH 7.0 using HCl
Mannitol 33 mg/ml
4. hGH 6 IU/ml
5 Adjusted to pH 7.0 using HCl
Sucrose 62 mg/ml
5. hGH 6 IU/ml
Adjusted to pH 6.5 using HCl
Mannitol 33 mg/ml
- 10 6. hGH 6 IU/ml
Adjusted to pH 6.5 using HCl
Sucrose 62 mg/ml
7. hGH 6 IU/ml
Adjusted to pH 7.0 using HCl
15 Mannitol 33 mg/ml
8. hGH 6 IU/ml
Adjusted to pH 7.0 using HCl
Sucrose 62 mg/ml
9. hGH 6 IU/ml
20 $\text{Na}_2\text{HPO}_4, 2\text{H}_2\text{O}$ 0.59 mg/ml
 $\text{NaH}_2\text{PO}_4, 2\text{H}_2\text{O}$ 0.53 mg/ml
Mannitol, 20.5 mg/ml
Adjusted to pH 7.0 using phosphoric acid

The lyophilized products are readily soluble and forms clear
25 aqueous solutions.

The amount of polymer before lyophilization (BL) and immediately after lyophilization, after 7 months at 4°C, after 7 months at 4°C plus 4 months at 37°C and after 7 months at 4°C plus 4 months at 25°C in % is stated in Table 5.

5 The amount of dimer in % is stated in Table 6.

The amount of desamido hGH in % is stated in Table 7, and

The amount of sulfoxide in % is stated in Table 8.

The amount of desamido hGH and sulfoxide was determined as in Examples 1-4.

10 The amount of dimer and polymer was determined by gp-HPLC.

Table 5

Buffer	Amount of Polymer in %				
	BL	T=0	7 mos. 4°C	7 mos. 4°C + 4 mos. 37°C	7 mos. 4°C + 4 mos. 25°C
5	No. 1	1.5			
	0.2	1.5	2.0	6.0	-
	No. 2	0.2			
	-	0.2	0.2	0.2	0.2
	No. 3	0.8			
10	0.2	1.0	1.8	4.0	2.6
	No. 4	0.2			
	-	<0.2	0.2	<0.2	<0.2
	No. 5	0.8			
	<0.2	0.7	1.6	3.1	3.0
10	No. 6	0.2			
	-	0.2	0.2	0.2	<0.2
	No. 7	1.3			
	0.2	1.4	2.0	3.1	2.3
	No. 8	0.2			
10	-	0.2	0.2	<0.2	<0.2
	No. 9	1.2			
	0.2	1.4	2.3	2.9	2.2

The amount of polymer is clearly lower for samples comprising sucrose.

Table 6

Buffer	Amount of Dimer in %				
	BL	T=0	7 mos. 4°C	7 mos. 4°C + 4 mos. 37°C	7 mos. 4°C + 4 mos. 25°C
5	No. 1	0.8 0.4	0.9 1.8	3.6	-
	No. 2	0.4 -	0.4 0.3	2.8	0.4
	No. 3	1.1 0.4	1.1 2.2	5.6	4.7
	No. 4	0.4 -	0.4 0.4	3.3	0.4
	No. 5	0.4 0.3	0.4 1.1	3.4	2.2
10	No. 6	0.4 -	0.4 0.3	3.1	0.3
	No. 7	0.9 0.3	0.9 1.4	4.7	3.3
	No. 8	0.9 -	0.9 0.4	3.0	0.4
	No. 9	0.6 0.5	0.7 1.0	4.3	2.2

The amount of dimer is clearly lower for samples comprising sucrose.

TABLE 7

Buffer	Amount of Desamido hGH in %				
	BL	T=0	7 mos. 4°C	7 mos. 4°C + 4 mos. 37°C	7 mos. 4°C + 4 mos. 25°C
5	No. 1	1.8 2.0	1.4 1.1	3.9	-
	No. 2	- 1.4 1.5	3.1	22.8	1.3
	No. 3	2.1 1.2 1.3	2.1	5.6	1.5
	No. 4	- 1.6 1.6	2.1	23.6	1.0
	No. 5	1.6 1.3 0.9	1.4	12.1	1.0
10	No. 6	- 1.2 1.3	1.6	23.0	1.4
	No. 7	2.0 1.4 1.6	1.0	4.8	4.6
	No. 8	- 1.5 1.4	1.9	20.2	2.9
	No. 9	2.1 1.7 1.5	2.0	9.9	3.6

The amount of desamido-hGH is very low for compositions comprising histidine after 7 months at 4°C + 4 months at 25°C.

TABLE 8

Buffer	Amount of Sulfoxide in %				
	BL	T=0	7 mos. 4°C	7 mos. 4°C + 4 mos. 37°C	7 mos. 4°C + 4 mos. 25°C
No. 1					
No. 2					1.0
5 No. 3					4.8
No. 4					1.1
No. 5					-
No. 6					1.0
No. 7					1.8
10 No. 8					1.4
No. 9					2.4

The amount of sulfoxide is clearly lower in samples comprising sucrose.

EXAMPLE 6

Stability of lyophilized preparations comprising histidine, mannitol and disaccharide.

The following preparations were made in the same manner as 5 disclosed in Example 5.

10. hGH 6 IU/ml
Adjusted to pH 6.5 using HCl
Sucrose 21 mg/ml
Mannitol 22 mg/ml
- 10 11. hGH 6 IU/ml
Adjusted to pH 7.0 using HCl
Sucrose 21 mg/ml
Mannitol 22 mg/ml
12. hGH 6 IU/ml
- 15 Adjusted to pH 7.0 using HCl
Trehalose 20 mg/ml
Mannitol 22 mg/ml

The amount of disamido-hGH, polymer, and dimer in % was determined before lyophilization (BL), at t=0, after three 20 months at 40°C and after 6 months at 25°C.

The results appear from the below Tables 9-11.

It appears that samples comprising mannitol and sucrose or trehalose show better stability than samples comprising only mannitol as bulking agent for the lyophilization.

Table 9

Buffer	Amount of Desamido-hGH in %			
	BL	T=0	3 mos. at 40°C	6 mos. at 25°C
No. 1		0.9	3.0	3.1
No. 10	1.3	0.9	1.7	2.4
No. 3		0.9	2.4	3.0
No. 11	0.9	1.4	1.2	2.0
No. 12		1.0	1.8	1.9
No. 9	0.7	0.7	2.8	3.4

Table 10

Buffer	Amount of Polymer in %			
	BL	T=0	3 mos. at 40°C	6 mos. at 25°C
No. 1		1.1	5.0	4.1
No. 10	0.4	0.6	1.8	1.3
No. 3		0.9	5.2	3.2
No. 11	0.5	0.6	1.5	1.1
No. 12		0.8	1.3	1.1
No. 9	0.4	0.6	1.9	1.6

Table 11

Buffer	Amount of Dimer in %			
	BL	T=0	3 mos. at 40°C	6 mos. at 25°C
No. 1		1.3	4.3	3.8
No. 10	0.5	0.9	1.8	1.6
No. 3		1.3	5.0	4.3
No. 11	0.6	1.2	2.2	1.8
No. 12		1.1	1.6	1.4
No. 9	0.6	0.9	1.0	2.3

5

EXAMPLE 7Formulation of a Pharmaceutical Preparation Containing Crystals of hGH:

Crystals were grown as described in example 4 and stored at 5 4°C. The crystals were then isolated by centrifugation and subsequent removal of the mother liquor. Then the crystals were lyophilized over night to achieve dry crystals without remaining organic solvent. A pharmaceutical suspension of the dried crystals was prepared according to the following formulation:

hGH crystals	1.3 mg/ml
Histidine	1.6 mg/ml
Zn(Ac) ₂ ·H ₂ O	0.1 mg/ml
Benzyl alcohol	0.9% (v/v)

15 pH was adjusted to 6.5 using HCl.

EXAMPLE 8

Example 7 was repeated with the exception that Zn(Ac)₂·H₂O was omitted, giving a suspension of the following formulation:

hGH crystals	1.3 mg/ml
20 Histidine	1.6 mg/ml
Benzyl alcohol	0.9% (v/v)

pH was adjusted to 6.2.

EXAMPLE 9

The crystals were treated in the same way as in example 7 and the following suspension was formulated:

hGH crystals	1.3 mg/ml
5 Histidine	1.33 mg/ml
NaCl	5.7 mg/ml
Benzyl alcohol	0.9% (v/v)

pH was adjusted to 6.2.

EXAMPLE 10

10 The crystals were treated in the same way as in example 7 and the following solution was prepared:

hGH crystals	1.3 mg/ml
Histidine	1.14 mg/ml
NaCl	9.0 mg/ml

15 pH was adjusted to 6.1.

EXAMPLE 11

In an analogous manner as described in EXAMPLE 1 biosynthetic human growth hormone was formulated in a concentration of 6 IU/ml in 0.9% benzyl alcohol at pH 6.5 in various concentrations of histidine, 0, 1, 2, 5, 10, 20, 30, 50, or 100 mM.

The samples were stored 7 days at 37°C and analyses for the contents of desamido, oxidized forms and dimers and polymers were performed in the same manner as described above. The results appear from the below Table 12 wherein the contents of desamido-hGH, dimers and polymers, and oxidized forms are determined by IE-HPLC, GP-HPLC and RP-HPLC and the contents of the cleaved forms of hGH is measured by IE-HPLC.

The amount of Dimer is low when the concentration is 1 mM histidine or above, for formation of desamido compounds concentrations of histidine of up to 30 mM gives acceptable results, and for formation of oxidized forms concentrations of histidine below 20 mM are preferred. An overall optimum is seen for a concentration of histidine of 5 mM.

Table 12

Concentrat. of Histidine mM	Amount of Desamido in %	Amount of Dimer in %	Amount of Polymers in %	Amount of Oxidized forms in %	Cleaved Forms in %	pH
0	7.7	0.7	<0.2	1.5	1.4	6.3
1	7.9	0.4	<0.2	1.5	1.2	6.4
2	8.7	0.3	<0.2	1.6	1.2	6.5
5	9.6	0.4	<0.2	1.7	n.d.	6.6
10	10.8	0.4	<0.2	1.7	n.d.	6.6
20	11.6	0.4	<0.2	2.0	n.d.	6.6
30	12.0	0.3	<0.2	2.1	n.d.	6.6
50	14.4	0.5	<0.2	3.8	n.d.	6.6
100	17.0	0.3	<0.2	2.6	n.d.	6.6

n.d. not detectable

REFERENCES

- 1) Y.-C.J. Wang and M.A. Hanson. Parenteral Formulations of Proteins and Peptides: Stability and Stabilizers. J. Parenteral Science and Technology 42 (Suppl.)
5 (1988) 53-525.
- 2) M.C. Manning, K. Patel, R.T. Borchardt. Stability of Protein Pharmaceuticals. Pharmaceutical Research 6
(11) (1989) 903-918.
- 3) B.A. Johnson, J.M. Shirokawa, W.S. Hancock, M.W.
10 Spellman, L.J. Basa and D.W. Asward. J.Biol.Chem. 264,
1462-71 (1989).
- 4) L.C. Teh et al., J.Biol.Chem., 262, 785-794 (1987).
- 5) G.W. Becker et al., Biotech.Appl.Biochem., 10, 326-337
(1988).
- 15 6) R.A. Houghten et al., Arch.Biochem.Biophys., 178, 350-
355 (1977).
- 7) R.M. Riggin et al., Anal.Biochem., 167, 199-209
(1987).
- 8) P. Gellerfors et al., Acta Paediatr.Scand (suppl),
20 370, 93-100 (1990).
- 9) M.J. Kaufman, Pharm.Res., 7 (3) 289-292 (1990).

CLAIMS

1. A pharmaceutical preparation comprising a growth hormon or a growth hormone derivative and histidine or a derivative of histidine in an amount of from 0.1 to 12 mg histidine or a derivative thereof per mg of growth hormone.
2. A pharmaceutical preparation as claimed in claim 1 in the form of a buffered aqueuos solution of growth hormone buffered with histidine buffer in a concentration from 1 mM to 100 mM.
- 10 3. A pharmaceutical preparation as claimed in claim 1 in the form of a buffered aqueous suspension of crystals of growth hormone buffered with histidine buffer.
4. A pharmaceutical preparation as claimed in any of claims 1-3 wherein the pH is adjusted to a value in the interval 2-15 9.
5. A pharmaceutical preparation as claimed in claim 4 wherein the pH is adjusted to a value in the interval from 5 to 8.
6. A pharmaceutical preparation as claimed in any of the preceeding claims further comprising a sugar alcohol or a 20 disaccharide or a mixture thereof.
7. A pharmaceutical preparation as claimed in any of the preceeding claims comprising mannitol or a disaccharide or a mixture thereof.

8. A pharmaceutical preparation as claimed in claim 7 wherein the disaccharide is sucrose or trehalose.
9. A pharmaceutical preparation as claimed in any of claims 1-8 wherein the growth hormone is hGH.
- 5 10. Crystals of growth hormone comprising histidine or a derivative of histidine.
11. Crystals as claimed in claim 10 wherein the growth hormone is hGH.
12. A method of preparing crystals of growth hormone or
10 growth hormone derivatives and histidine or a derivative of histidine comprising the steps of:
- a) forming a solution of growth hormone or a growth hormone derivative in a solvent and adding histidine or a derivative of histidine and optionally adjusting the pH to a value from
15 5 to 8 using hydrochloric acid.
 - b) adding organic or inorganic cations,
 - c) crystallizing the solution at a temperature from about 0°C to about 30°C, and
 - d) isolating the crystals formed by a manner known per se.
- 20 13. A method as claimed in claim 12 wherein the solvent in step a) is selected from short chained aliphatic, alicyclic or aromatic alcohols and ketones.

14. A method as claimed in claim 11 or 12 wherein the growth hormone is hGH.

1/1




FIG. 1




FIG. 2

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 92/00379

A. CLASSIFICATION OF SUBJECT MATTER

IPC5: A61K 37/36

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC5: A61K, C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

MEDLINE, EMBASE, WPI, CLAIMS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP, A2, 0374120 (MONSANTO COMPANY), 20 June 1990 (20.06.90), whole document, especially claim 16 --	1-14
X	US, A, 4816568 (HAMILTON, JR. ET AL), 28 March 1989 (28.03.89), column 2, line 67 - column 3, line 16; column 4, line 36 - line 44, claims 17,27 --	1-14
X	US, A, 4917685 (VISWANATHAN ET AL), 17 April 1990 (17.04.90) -----	1-14

☐

Further documents are listed in the continuation of Box C.

☒

See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

7 April 1993

Date of mailing of the international search report

13 -04- 1993

Name and mailing address of the ISA/

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

Jonny Brun

Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT
Information on patent family members

26/02/93

International application No.
PCT/DK 92/00379

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A2- 0374120	20/06/90	AU-A- 4617689 CA-A- 2005226 JP-A- 2204418	21/06/90 13/06/90 14/08/90
US-A- 4816568	28/03/89	NONE	
US-A- 4917685	17/04/90	NONE	

